Study: HPV vaccine prevents cervical cancer

null Research funded by GlaxoSmithKline studied women ages 15 to 25 who received Cervarix, the company's vaccine.

The vaccine was injected into patients who had evidence of current or previous HPV infection or high-grade pap smear results and women with no evidence of current or previous infection.

GlaxoSmithKlilne said Cervarix was 98 percent effective against HPV types 16 or 18.

Cervarix has not been approved in the United States or Japan, but is available in the European Union and other countries.

If Cervarix is approved by the Food and Drug Administration it would compete with Merck's HPV vaccine Gardasil.

Report Typo |  Send Tip |  Get Alerts | Most Popular
Follow @abc7 on Twitter  |  Become a fan on Facebook

Copyright © 2019 KABC-TV. All Rights Reserved.